CEPI puts $60m behind three Ebola vaccine candidates
Moderna has been awarded $50m from CEPI for a Bundibugyo ebolavirus vaccine candidate, with funding also made available to two other candidates.
Servier wagers $2.65bn on Edgewise muscular dystrophy drug
Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.
ASCO26: Verzenio gives hope of liposarcoma treatment advance
The SARCO41 study suggests Lilly's Verzenio could become the first targeted therapy for rare, aggressive tumour dedifferentiated liposarcoma.
DHSC lauds benefits of single patient record ahead of debate
The NHS digital single patient record (SPR) could result in 20,000 fewer A&E visits in England per year and save £20m a year, says the UK government.
ASCO26: Could AL amyloidosis see a new crop of therapies?
Trials of AstraZeneca's anselamimab and Regeneron's Lynozyfic could deliver much-needed new therapeutic options for rare disease AL amyloidosis.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Inizio Launches Intelligent Congress to Turn Event Investmen...
Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery